Compounds > atenolol
Page last updated: 2024-10-23

atenolol and ANS (Autonomic Nervous System) Diseases

atenolol has been researched along with ANS (Autonomic Nervous System) Diseases in 6 studies

Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.

Research Excerpts

ExcerptRelevanceReference
"We studied 49 patients with type 1 diabetes (age 50."2.73Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade. ( Crea, F; Ghirlanda, G; Infusino, F; Lanza, GA; Manto, A; Musella, T; Navarese, EP; Pitocco, D; Sestito, A; Sgueglia, GA, 2007)
"Neurally mediated hypotension is now recognised as a common cause of otherwise unexplained recurrent syncope, but has not been reported in association with chronic fatigue."1.29Is neurally mediated hypotension an unrecognised cause of chronic fatigue? ( Bou-Holaigah, I; Calkins, H; Kan, JS; Rowe, PC, 1995)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's2 (33.33)18.2507
2000's3 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eguchi, K1
Pickering, TG1
Ishikawa, J1
Hoshide, S1
Komori, T1
Tomizawa, H1
Shimada, K1
Kario, K1
Lanza, GA1
Pitocco, D1
Navarese, EP1
Sestito, A1
Sgueglia, GA1
Manto, A1
Infusino, F1
Musella, T1
Ghirlanda, G1
Crea, F1
Djonlagić, H1
Bos, I1
Diederich, KW1
Rowe, PC1
Bou-Holaigah, I1
Kan, JS1
Calkins, H1
Grubb, BP1
Kosinski, DJ1
Boehm, K1
Kip, K1
Chelimsky, G1
Chelimsky, T1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Essential Arterial Hypotension and Allostasis Registry[NCT02018497]5,000 participants (Anticipated)Observational [Patient Registry]1995-01-31Recruiting
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730]Phase 1/Phase 28 participants (Actual)Interventional2011-08-15Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Trials

1 trial available for atenolol and ANS (Autonomic Nervous System) Diseases

ArticleYear
Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade.
    European heart journal, 2007, Volume: 28, Issue:7

    Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Autonomic Nervous System Diseases; C-Re

2007

Other Studies

5 other studies available for atenolol and ANS (Autonomic Nervous System) Diseases

ArticleYear
Severe orthostatic hypotension with diabetic autonomic neuropathy successfully treated with a beta(1)-blocker: a case report.
    Journal of human hypertension, 2006, Volume: 20, Issue:10

    Topics: Adrenergic Fibers; Antihypertensive Agents; Atenolol; Autonomic Nervous System Diseases; Diabetic Ne

2006
[Sympathetic ganglionitis in the hereditary syndrome of QT prolongation (Romano-Ward syndrome); intracardiac registration of after-potentials (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1982, Apr-30, Volume: 107, Issue:17

    Topics: Adult; Arrhythmias, Cardiac; Atenolol; Autonomic Nervous System Diseases; Autopsy; Electrocardiograp

1982
Is neurally mediated hypotension an unrecognised cause of chronic fatigue?
    Lancet (London, England), 1995, Mar-11, Volume: 345, Issue:8950

    Topics: Adolescent; Atenolol; Autonomic Nervous System Diseases; Blood Pressure; Child; Disopyramide; Fatigu

1995
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
Familial association of autonomic and gastrointestinal symptoms.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2001, Volume: 11, Issue:6

    Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Autonomic Nervous System Diseases; Child; Fatigue; Fem

2001